ATE438662T1 - Verbesserte fc-fusionsproteine - Google Patents

Verbesserte fc-fusionsproteine

Info

Publication number
ATE438662T1
ATE438662T1 AT04723552T AT04723552T ATE438662T1 AT E438662 T1 ATE438662 T1 AT E438662T1 AT 04723552 T AT04723552 T AT 04723552T AT 04723552 T AT04723552 T AT 04723552T AT E438662 T1 ATE438662 T1 AT E438662T1
Authority
AT
Austria
Prior art keywords
domain
fusion proteins
improved
ligand
receptor
Prior art date
Application number
AT04723552T
Other languages
English (en)
Inventor
Henning Walczak
Original Assignee
Apogenix Gmbh
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh, Deutsches Krebsforsch filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of ATE438662T1 publication Critical patent/ATE438662T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT04723552T 2003-03-26 2004-03-26 Verbesserte fc-fusionsproteine ATE438662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006949 2003-03-26
PCT/EP2004/003239 WO2004085478A2 (en) 2003-03-26 2004-03-26 Improved fc fusion proteins

Publications (1)

Publication Number Publication Date
ATE438662T1 true ATE438662T1 (de) 2009-08-15

Family

ID=33040920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723552T ATE438662T1 (de) 2003-03-26 2004-03-26 Verbesserte fc-fusionsproteine

Country Status (15)

Country Link
US (2) US8007813B2 (de)
EP (2) EP1606319A2 (de)
JP (2) JP2007533595A (de)
AT (1) ATE438662T1 (de)
AU (2) AU2004224122A1 (de)
CA (2) CA2520138C (de)
CY (1) CY1109536T1 (de)
DE (1) DE602004022390D1 (de)
DK (1) DK1606318T3 (de)
ES (1) ES2327409T3 (de)
HK (1) HK1077592A1 (de)
PL (1) PL1606318T3 (de)
PT (1) PT1606318E (de)
SI (1) SI1606318T1 (de)
WO (2) WO2004085479A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4944032B2 (ja) 2004-09-13 2012-05-30 ジェンザイム・コーポレーション 多量体構築物
EP2510939A1 (de) * 2005-02-03 2012-10-17 Coda Therapeutics Limited Anti-Connexin- Peptide und deren therapeutischen Verwendungen
JP2009505989A (ja) 2005-08-15 2009-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＶＥＧＦによって活性化されるＦａｓリガンド
BRPI0619056A2 (pt) * 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
WO2007070948A1 (en) * 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
US7846439B2 (en) 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
ATE545704T1 (de) * 2006-05-17 2012-03-15 Uni Klinikum Tuebingen Antientzündliches fusionsprotein
DK2101877T3 (da) * 2006-12-28 2013-09-23 Deutsches Krebsforsch Neutralisering af virkningen af CD95 til blokering af invasion af glioblastomceller in vivo
EP2185589B1 (de) 2007-06-01 2016-01-06 University of Maryland, Baltimore Fc-rezeptor-bindemittel für konstante immunoglobulinregion
ES2524553T3 (es) 2008-06-17 2014-12-10 Apogenix Gmbh Receptores multiméricos de TNF
EP2318441A2 (de) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Verwendung eines cd95-inhibitors zur behandlung von entzündlichen erkrankungen
EP2536747B1 (de) 2010-02-19 2017-09-27 Université de Liège Polynukleotide zu heilung von influenza a virus induzierten krankheiten, die für ein modifiertes protein kodieren, dieses protein, und ein transgenischer tier die dieses protein exprimiert
CN105820256A (zh) 2010-07-28 2016-08-03 格利克尼克股份有限公司 天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
EP2601214B1 (de) 2010-08-06 2017-11-01 Genzyme Corporation Vegf-antagonistenzusammensetzungen und ihre verwendung
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
EP2807194A4 (de) * 2012-01-27 2015-12-02 Gliknik Inc Fusionsproteine mit igg2-scharnierdomänen
EP2867253B1 (de) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Verfahren zur auswahl und herstellung massgeschneiderter, hochselektiver und multispezifischer targeting-einheiten mit mindestens zwei verschiedenen bindungseinheiten sowie verwendungen davon
BR112014028368A2 (pt) * 2012-06-27 2017-11-14 Hoffmann La Roche método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
US9315570B2 (en) 2012-07-18 2016-04-19 Apogenix Gmbh Composition comprising a mixture of CD95-Fc isoforms and methods of producing same
KR102145999B1 (ko) 2012-07-18 2020-08-19 아포게닉스 아게 Ｍｄｓ 치료를 위한 ｃｄ９５ 신호전달 경로의 억제제
RU2015109591A (ru) 2012-08-20 2016-10-20 Гликник Инк. Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами
US10189887B2 (en) 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
WO2016118577A1 (en) * 2015-01-22 2016-07-28 Medimmune, Llc Thymosin-beta-four fusion proteins
EP3292143B1 (de) 2015-05-04 2019-08-21 Apogenix AG Einkettige cd40-rezeptoragonistenproteine
AU2016342420B2 (en) 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
JP6917368B2 (ja) 2015-10-23 2021-08-11 アポジェニックス アーゲー 一本鎖ｃｄ２７受容体アゴニストタンパク質
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
WO2020205662A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Inc. Ex vivo methods for producing a t cell therapeutic and related compositions and methods
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc A method for producing tumor-reactive t cells using modulatory substances
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
GB202016058D0 (en) 2020-10-09 2020-11-25 Ucl Business Ltd Therapeautic treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
DE4447484C2 (de) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
EP0965637B1 (de) 1996-05-02 2005-07-20 Mochida Pharmaceutical Co., Ltd. Fas ANTIGEN-DERIVATE
DE69730358T2 (de) 1996-10-31 2004-12-30 Mochida Pharmaceutical Co. Ltd. Fas-Antagonist FÜR DIE PROPHYLAXE ODER THERAPIE VON GVHD
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
ZA981478B (en) 1997-02-21 1998-08-24 Vlaams Interuniv Inst Biotech Use of interleukin-15
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ， インコーポレイテッド Ｔｒａｉｌレセプター、これをコードする核酸、およびその使用方法
BR9909328A (pt) 1998-03-30 2000-12-12 Lilly Co Eli Aplicações terapêuticas de polipeptìdeos flint maduros (mflint) ou opg3, um membro da superfamìlia dos receptores para tnf
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
CA2369371A1 (en) * 1999-05-04 2000-11-09 Human Genome Sciences, Inc. Death domain containing receptor 5
DE19959049A1 (de) 1999-12-07 2001-06-28 Deutsches Krebsforsch Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
MXPA03007323A (es) 2001-02-19 2003-12-12 Merck Patent Gmbh Proteinas artificiales con inmunogenicidad reducida.
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE10122140A1 (de) * 2001-05-08 2002-11-28 Apotech Res & Dev Ltd Rekombinante Fusionsproteine und deren Trimere
US7064189B2 (en) * 2001-05-25 2006-06-20 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
DE10160248A1 (de) 2001-12-07 2003-06-26 Alexander Cherkasky Fusionsproteinen enthaltend Fc-Regionen

Also Published As

Publication number Publication date
SI1606318T1 (sl) 2009-12-31
PL1606318T3 (pl) 2010-01-29
EP1606319A2 (de) 2005-12-21
JP2007524365A (ja) 2007-08-30
EP1606318A2 (de) 2005-12-21
ES2327409T3 (es) 2009-10-29
HK1077592A1 (zh) 2006-02-17
WO2004085478A3 (en) 2005-01-06
WO2004085479A3 (en) 2004-11-25
CA2520254A1 (en) 2004-10-07
WO2004085478A2 (en) 2004-10-07
CY1109536T1 (el) 2014-08-13
PT1606318E (pt) 2009-11-10
AU2004224122A1 (en) 2004-10-07
JP4741464B2 (ja) 2011-08-03
CA2520138A1 (en) 2004-10-07
CA2520138C (en) 2017-05-23
US20070269449A1 (en) 2007-11-22
WO2004085479A2 (en) 2004-10-07
DK1606318T3 (da) 2009-11-02
US20110305697A1 (en) 2011-12-15
AU2004224123A1 (en) 2004-10-07
US8007813B2 (en) 2011-08-30
DE602004022390D1 (de) 2009-09-17
JP2007533595A (ja) 2007-11-22
EP1606318B1 (de) 2009-08-05

Similar Documents

Publication Publication Date Title
ATE438662T1 (de) Verbesserte fc-fusionsproteine
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
RS51318B (sr) Varijante imunoglobulina i njihova upotreba
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
NO2011003I1 (no) Dimensk fusjonsprotein bestående av de ligandbindende cfomener av de ekstacellulære deler av human type I interieukm-1 reseptor (IL-1R1) og IL-1 reseptor hjelpeprotein bundet (IL-I-RAcP) bundet i tinje til Fc-delen av humant IgG
PT1047781E (pt) Receptores de il-18
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
ES2187954T3 (es) Anticuerpos anti-integrina avb3 antagonistas.
WO2003034903A3 (en) Psma antibodies and protein multimers
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
DK1392359T3 (da) Specifikke bindingsproteiner og deres anvendelser
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
TR199902878T2 (xx) Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
DK1355919T3 (da) Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
UY28641A1 (es) Anticuerpos
NO20005637L (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
ATE388227T1 (de) Gemisch mindestens zweier fusionsproteine sowie ihre herstellung und verwendung
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1606318

Country of ref document: EP